Interview with Igor Krylov, CEO, Pharmstandard
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
Address: Likhachevsky drive 5 «B», Moscow region, Dolgoprudny, 141700,Russia
Tel: +7 (495) 970-0030/32
Web: http://pharmstd.ru/
Pharmstandard is the leader of Russian pharmaceutical industry in R&D and production of the medicinal products.
In 2010, Pharmstandard became №2 among all pharmaceutical companies represented in Russia and market share reached 4.2%.1 Since 2007 Pharmstandard keeps its leading position in commercial segment and remains strong leader among the domestic pharmaceutical company-manufacturers.*1
Pharmstandard became the winner of the national business award ‘Company of the Year 2010’ according to RBC.*2
During the tenth anniversary of «Platinum Ounce 2010», the open competition among professionals of pharma business, Pharmstandard was awarded in the nominations for «The Company of the Year – the Russian pharmaceutical products manufacturer» and «The Company of Decade – the Russian pharmaceutical products manufacturer».
Pharmstandard operates four modern pharmaceutical manufacturing facilities: JSC «Pharmstandard-Leksredstva» in Kursk, JSC «Pharmstandard-UfaVITA» in Ufa, JSC «Pharmstandard-Tomskhimpharm» in Tomsk, PJSC «Pharmstandard-Biolek» in Kharkov (Ukraine) and medical equipment factory JSC «TZMOI» in Tyumen.
The Company has invested approximately RUR 3 billion RUR in modernization and development of production capacities reaching more than 1,35 bln units per year. All the production facilities fully comply with Russian manufacturing standards. Six production lines of JSC «Pharmstandard-Leksredstva» meet EU GMP requirements.
Pharmstandard portfolio includes over 250 products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer. More than 100 products offered by Pharmstandard are included in the List of Vital and Essential Pharmaceuticals.
In 2004-1H2011, we developed and introduced over 55 new pharmaceutical products in close collaboration with the leading scientific centers of Russia. Pharmstandard is the partner of the joint venture biotechnological project «Generium» in order to develop and manufacture innovative biological products within the state program of import substitution.
Pharmstandard became a public company on 4 may 2007 by offering to the public 27.57% of its share capital in the form of GDR on the London Stock Exchange (LSE) and 18.12% of its share capital in the form of ordinary shares on two local stock exchanges (RTS, MICEX). Approximately 54.31%of voting shares of OJSC «Pharmstandard» are held by «Augment Investments Limited».
www.pharmstd.ru
1 Pharmexpert (CMR) 2010 market data.
2 The annual national business award ‘Company of the Year’ is organized by RBK Holdings.
Pharmstandard portfolio includes over 250 products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer. More than 100 products offered by Pharmstandard are included in the List of Vital and Essential Pharmaceuticals.
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of…
In spring of 2010, Protek became the first Russian wholesaler to enter the public stock market, raising $400Mn in the biggest Russian IPO since 2007. You offered the IPO directly…
PAREXEL prides itself on improving the time schedule of a product launch. What is the significance of time-to-market in the healthcare industry, and how can PAREXEL expedite the process better…
Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you…
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
You worked for ten years at Schering-Plough—one of the largest pharmaceutical companies in the world. In February of last year, you joined Merz Pharma, a much smaller player. Some may…
Russia and India have recently held a number of discussions regarding increased cooperation within the pharmaceutical sector. For example, the two nation’s health ministers have discussed decreasing administrative barriers to…
Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have…
Petrovax has always been an innovative company, making it quite unique in Russia where the domestic industry is predominantly comprised of generics manufacturers. How would you describe the positioning of…
After a long history in Philips, this is your first tenure as a regional CEO. Having been at this position for less than a year, what are your impressions of…
You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed,…
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
See our Cookie Privacy Policy Here
